Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

AV-105

  Cat. No.:  DC40273   Featured
Chemical Structure
1205550-99-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
AV-105 is a tosylate precursor compound derived from ​Florbetapir (18F), a radiolabeled styrylpyridine derivative referenced in ​patent WO2010078370A1 (Example 1.5). This precursor plays a crucial role in the synthesis of ​18F-radiolabeled imaging agents, particularly for ​positron emission tomography (PET) applications.
Cas No.: 1205550-99-7
Chemical Name: AV-105
Synonyms: AV-105;AV 105;AV105
SMILES: O=C(OC(C)(C)C)N(C)C1=CC=C(/C=C/C2=CC=C(OCCOCCOCCOS(=O)(C3=CC=C(C)C=C3)=O)N=C2)C=C1
Formula: C32H40N2O8S
M.Wt: 612.73
Purity: >98%
Sotrage: Pure form-20°C3 years4°C2 yearsIn solvent-80°C6 months-20°C1 month
Publication: [1]. Tyler Benedum, et al. Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof. WO2010078370A1.
Description: AV-105 is a Florbetapir (18F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize 18F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain[1].
In Vitro: The AV-105 synthesis method utilizes a primary tosylate instead of a primary mesylate as an active leaving group. Use of the tosylate precursor for radiofluorination is beneficial, at least for the reason that the tosylate generated during the radiofluorination reaction is readily removed by chromatographic means from the 18F-radiolabeled imaging product[1].
References: [1]. Tyler Benedum, et al. Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof. WO2010078370A1.
MSDS
TITLE DOWNLOAD
MSDS_23286_DC40273_1205550-99-7
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC67437 PI-2620 precursor PI-2620 precursor is the precursor of PI2620. 18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders.
DC60818 mono-Boc-Br MK-6240 Precursor mono-Boc-Br MK-6240 Precursor is the precusor of MK-6240.. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
DC67285 DOTA-Octreotide
DC67284 NOTA-NOC
DC60791 Cholestify Precursor Precursor of Cholestify,18F-Cholestify, which binds cytochrome P450 46A1, detected cholesterol breakdown in the mammalian brain. CYP46A1 converts cholesterol to 24-hydroxycholesterol, a form easily eliminated from the brain.
DC60790 DesMEM AZD4694 DesMEM AZD4694(AZD4694 Precursor 1)is the precursor of [18F] AZD4694 for the synthesis of [18F] AZD4694, an amyloid-β imaging ligand with high affinity for amyloid-β plaques.
DC66469 DOTA-NOC DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging.
DC66468 NOTA-octreotide NOTA-octreotide is a ligand for making [18F]AlF-NOTA-octreotide, which is a PET/CT imaging agent for somatostatin receptor imaging in neuroendocrine tumor patients
DC66467 F-PSMA 1007
DC66465 Pentanedioate Pentanedioate is a valuable starting material for the synthesis of PSMA inhibitors due to its flexible structure and functional groups that mimic natural PSMA ligands. By leveraging its chemical properties, researchers can develop potent and selective PSMA-targeting agents for diagnostic imaging, targeted therapy, and theranostic applications in prostate cancer and other PSMA-expressing malignancies. Its role in drug discovery highlights the importance of simple organic molecules in the development of advanced cancer therapies.
X